Array Biopharma, Inc. (ARRY) Reports Q1 EPS Loss of $0.06, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.24 --0%
EPS Growth %: -70.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -70.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.06), $0.13 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $17.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Array Technologies (ARRY) to Neutral
- Radiant Logistics (RLGT) Tops Q4 EPS by 9c
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
